Dr. Dana Zakalik
Claim this profileBeaumont Hospital - Farmington Hills
Expert in Cancer
Studies Ovarian Cancer
12 reported clinical trials
46 drugs studied
Area of expertise
1Cancer
Global LeaderStage IV
KRAS positive
NRAS positive
2Ovarian Cancer
KRAS positive
NRAS positive
BRCA1 positive
Affiliated Hospitals
Clinical Trials Dana Zakalik is currently running
Selumetinib + Olaparib
for Ovarian and Endometrial Cancer
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of olaparib to selumetinib could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to selumetinib alone.
Recruiting1 award Phase 2
Olaparib
for Pancreatic Cancer
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.
Recruiting0 awards Phase 232 criteria
More about Dana Zakalik
Clinical Trial Related1 year of experience running clinical trials · Led 12 trials as a Principal Investigator · 10 Active Clinical TrialsTreatments Dana Zakalik has experience with
- Binimetinib
- Ipatasertib
- Olaparib
- Palbociclib
- Biospecimen Collection
- Sotorasib
Breakdown of trials Dana Zakalik has run
Cancer
Ovarian Cancer
Tumors
Recurrence
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Dana Zakalik specialize in?
Dana Zakalik focuses on Cancer and Ovarian Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are KRAS positive.
Is Dana Zakalik currently recruiting for clinical trials?
Yes, Dana Zakalik is currently recruiting for 10 clinical trials in Farmington Hills Michigan. If you're interested in participating, you should apply.
Are there any treatments that Dana Zakalik has studied deeply?
Yes, Dana Zakalik has studied treatments such as Binimetinib, Ipatasertib, Olaparib.
What is the best way to schedule an appointment with Dana Zakalik?
Apply for one of the trials that Dana Zakalik is conducting.
What is the office address of Dana Zakalik?
The office of Dana Zakalik is located at: Beaumont Hospital - Farmington Hills, Farmington Hills, Michigan 48336 United States. This is the address for their practice at the Beaumont Hospital - Farmington Hills.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.